Aptevo reports tumor-cell killing under immunosuppressive conditions in preclinical studies
APVO•Aptevo Therapeutics presented preclinical findings on November 7, 2026, showing APVO451 and APVO452 killed tumor cells under immunosuppressive conditions, while APVO711 combined CD40 activation with PD-L1 checkpoint blockade.
1. Preclinical findings
Aptevo Therapeutics presented solid-tumor immunotherapy findings at the Society for Immunotherapy of Cancer meeting on November 7, 2026. APVO451 and APVO452 killed tumor cells under immunosuppressive conditions, supporting further development of treatments combining CD40 activation with T-cell engagement. In preclinical studies, APVO711 combined CD40 activation with PD-L1 checkpoint blockade.
